Remington Medical has confirmed that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its updated VascuChek® Doppler, marking the official commercial launch of the second-generation device. Designed for both clinical and surgical applications, VascuChek is a pioneering handheld vascular Doppler, and the latest version introduces a Bluetooth® external speaker to deliver enhanced audio clarity and greater volume for more precise assessment of blood flow during surgical procedures.
The newly launched device enhances the original model by retaining its lightweight handheld form and cordless operation, making vascular monitoring even more convenient. Each system includes a handheld transceiver and a disposable, detachable probe available in both surgical and clinical formats. The probe connects to the transceiver in much the same way as an electric toothbrush head attaches to its handle.
With its patented antiseptic sheath and disposable probe design, VascuChek remains the only wireless, handheld Doppler on the market to receive FDA clearance for use in evaluating intraoperative and subcutaneous blood flow within a sterile surgical field.
VascuChek incorporates dual internal speakers to provide immediate auditory feedback when clinicians assess a patient's vascular flow. For situations requiring amplified sound, users can easily switch the audio output to the integrated Bluetooth® speaker located in the device's charging base.
"When it launched in 2022, VascuChek was a big leap forward for convenience and ease, offering surgeons a cordless Doppler that gave them full control," said Attly Aycock, CEO of Remington Medical. "The new device builds on that and adds even better audio clarity and volume; we made these updates based on valuable feedback from surgeons who've been using VascuChek in their ORs. We're confident that VascuChek can transform operational efficiencies for the more than 38,000 operating rooms across the U.S."
The VascuChek system is suited for a wide range of healthcare professionals, including vascular, cardiac, orthopaedic, podiatry and general surgeons, as well as cardiologists and surgical nursing staff. VascuChek 2.0 is now available for purchase within the United States.
For inquiries about VascuChek, or to schedule a product demonstration, please visit https://vascuchek.com/contact/
source:newsreleases.co.uk
Active Biotech to receive US patent for tasquinimod formulation
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Clearmind Medicine advances global CMND-100 AUD trial with first patient enrolled in Israel
NeuroSense's PrimeC receives FDA clearance for pivotal Phase 3 trial in ALS
Made Scientific enters manufacturing partnership with Cellergy Therapeutics
Novartis' Itvisma granted US FDA approval for spinal muscular atrophy treatment
Avidity Biosciences announces US Managed Access Program for delpacibart zotadirsen (del-zota)
Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination
European Commission approves Celltrion's Remsima IV liquid formulation